The nationwide fecal immunochemical test-based screening program has influenced surgical care for patients with colorectal cancer (CRC) in the Netherlands, although these implications have not been studied in much detail so far.
W ith an estimated number of 15 800 new cases and 5100 deaths in 2015, colorectal cancer (CRC) is the second most common cause of cancer-related death in the Netherlands. 1 To increase CRC-specific survival, organized screening programs have been endorsed by the European Commission. 2 A national CRC screening program was introduced in 2014 in the Netherlands. The program is gradually implemented with a complete rollout by 2019. By then, all men and women aged 55 to 75 years will be invited to participate in the program by a biennial fecal immunochemical test (FIT) .
Because the FIT has a sensitivity of around 75% for CRC, screening is an iterative process. 3 In the Netherlands, participation rates are high compared with other countries 4 To allow a comprehensive appreciation of the CRC screening program targeting a supposedly asymptomatic population, an integrated view of the harms and benefits is necessary, including those of surgical treatment. However, literature on morbidity and mortality after surgical treatment of CRC detected through a screening program is limited. 7 The primary aim of this study was to examine whether patients undergoing surgery for CRC following diagnosis through the FIT-based screening program have different surgical outcomes compared with nonscreening patients and to what extent an extensive case-mix correction can adjust for any differences found. In addition, an overview is given of patient, tumor, and treatment characteristics of the surgically treated screen-detected CRCs in the Netherlands, based on the data registered in the Dutch ColoRectal Audit (DCRA).
Methods
Data from the DCRA, formerly known as the Dutch Surgical Colorectal Audit (ie, DSCA), were extracted for this study. 8 In this nationwide and disease-specific audit, data on various patient, tumor, treatment, and short-term (30-day) outcome characteristics are collected of every patient undergoing a resection for primary CRC in the Netherlands.
Patient Selection
The DCRA is an obligatory audit from the inspectorate of health care, which required no informed consent from patients for data collection. Data analyses were performed on an anonymized dataset and do not need ethical approval according to Dutch law. Eligibility criteria required patients to have undergone surgical treatment for primary CRC between January 1, 2011, and December 31, 2016 , and be registered in the DCRA before March 31, 2017 (n = 63 370) . Minimal data requirements were information on tumor location, date of surgery, and 30-day or in-hospital mortality (n = 63 136). For the objective of this study, only patients in whom the surgery took place in an elective setting were selected (n = 55 531). Furthermore, the heterogenous group of patients with multiple synchronous colorectal tumors (n = 1873) were excluded. 9 This resulted in 53 658 patients eligible for analyses. For trend analysis, all patients (2011) (2012) (2013) (2014) (2015) (2016) were selected (eFigure in the Supplement). For the comparison of the outcomes of screen-detected vs nonscreen-detected patients, all patients were selected who underwent surgery since the start of the nationwide CRC screening program in 2014.
Data
The following data were retrospectively extracted from the DCRA database: patient characteristics, disease characteristics, (pre)procedural characteristics, postoperative outcomes within 30 days after resection or in hospital, and whether the patients were referred through the screening program. Invited birth cohorts for the screening program in the 3 years were 1938 to 1941, 1945 to 1955, and 1957 . Only patients who were referred through the screenings program after a positive FIT and were diagnosed as having a CRC that was surgically resected were marked as screen-detected CRC. All missing values were 10% or less and no imputation was conducted (eTable 1 and eTable 2 in the Supplement).
Outcome Parameters
Outcome parameters were nonsurgical postoperative complications (pulmonary, cardiac, thromboembolic, infectious, neurologic, other), surgical postoperative complications, complicated course (postoperative complication leading to a hospital stay of >14 days and/or a reintervention and/or mortality), and postoperative mortality (≤30 days or in hospital during the same admission).
Data Analysis
Colon and rectal cancer were analyzed separately. To evaluate trends over time and the impact of the implementation of the nationwide screening program on the DCRA, data on complicated course and mortality were evaluated for all included patients, according to year of registration. Differences in baseline characteristics were compared between non-screendetected patients during 2011 to 2013 and 2014 to 2016 and between screen-detected and non-screen-detected patients during 2014 to 2016. Patients registered between 2014 to 2016 were stratified into homogenous subgroups based on known risk factors (age, American Society of Anesthesiologists [ASA] classification, cancer stage), and differences in outcomes (complicated course and mortality) of screen-detected vs non-screen-detected patients were assessed.
Absolute risk differences with corresponding 95% CIs were compared between screen-detected and non-screendetected patients. Differences in categorical variables were analyzed using a χ 2 test and for nonnormally distributed continuous variables (eg, length of stay), a nonparametric MannWhitney U test was used. To evaluate differences in outcomes between screen-detected and non-screen-detected patients from 2014 to 2016, univariable and multivariable logistic regression analyses were performed, and the results were expressed as odds ratios with corresponding 95% CIs. To adjust for differences in case mix, factors included in the multivariable analysis consisted of age, sex, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), ASA score, Charlson comorbidity score, any tumorrelated complication, previous abdominal surgery (not further specified), pathological (p)T-classification, presence of metastasis, additional resection due to tumor invasion, and additional resection due to metastasis. For colon cancer, the location of the tumor within the colon (cecum, appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid) was added to the case mix. For case-mix correction in rectal cancer, tumor distance from the anal verge, clinical (c)T-classification, preoperative radiotherapy, and surgical procedure (low anterior resection, abdominoperineal resection, or other procedure) were added to the model. Preoperative radiotherapy was categorized as no radiotherapy, short-course radiotherapy with immediate (≤3 week) surgery, short-course radiotherapy with delayed (>3 week) surgery, or chemoradiotherapy/long-course radiotherapy. A P value less than .05 was considered statistically significant. SPSS 24.0 Statistics for Windows (IBM Corp) was used for all analyses.
Results

Baseline Characteristics
In total, 36 242 patients with colon cancer and 17 416 patients with rectal cancer were included for analysis. (2011) (2012) (2013) , the nonscreen-detected patients between 2014 and 2016 had a higher ASA score, BMI, and Charlson score. For patients with rectal cancer, only BMI and Charlson score were significantly different. Comparing non-screen-detected patients with screendetected patients between 2014 to 2016, almost all patient and tumor characteristics differed significantly. This was also found for the different workup and surgery characteristics and length of stay ( Table 2 ). For patients with rectal cancer, no significant differences were found between non-screen-detected patients compared with screen-detected patients for the proportion of patients being discussed in a multidisciplinary team meeting and the proportion of patients being converted after an initial laparoscopic approach.
Adverse Outcome Over Time Figure 1 shows the crude trend of complicated course and mortality of patients with primary CRC between 2011 and 2016 for colon ( Figure 1A ) and rectal cancer ( Figure 1B) . Patients with colon cancer diagnosed through the screening program had a complicated course rate ranging from 11% (2014) to 8.6% (2016) and a mortality rate declining from 1.4% (2014) to 0.4% (2015 and 2016) . In the same time (2014) (2015) (2016) , complicated course for patients with non-screen-detected CRC ranged from 15.3% (2014) to 13.3% (2016) and mortality from 1.9% (2014) 
Stratified Comparison of Screen-Detected vs Non-Screen-Detected CRC
In Figure 2 , patients with screen-detected and non-screendetected CRC are compared regarding complicated course and mortality. Patients diagnosed as having colon cancer through the screening program had a significantly lower postoperative complication rate and mortality compared with nonscreen-detected patients for stage I to III, with a similar (nonsignificant) result for stage IV (Figure 2A ).
For patients with rectal cancer, higher stage was associated with an increase in complication rate in screen-detected patients, and this was more pronounced compared with nonscreen-detected patients ( Figure 2B ). No significant differences of complication rates between screen-detected and nonscreen-detected patients were found for each of the cancer stages. Similar mortality rates were found for stage I to III, with a significantly higher mortality rate after resection of screendetected compared with non-screen-detected stage IV rectal cancer. (17) 2678 (17) . 96 160 (3) <.001 c 2025 (26) 2040 (26) . 64 48 (3) <.001 c 61-70 4572 (29) 4621 (29) 3009 (64) 2693 (34) 2667 (34) 1068 (68) 71-80 5452 (34) 5596 (35) 1527 (33) 2335 (30) 2326 (29) 466 (30) ≥81 2957 (19) 3029 ( (14) 2422 (15) 287 (6) 323 (4) 343 (4) 24 (2) (continued) In Figure 2C , complicated course and mortality are shown for stage I to III colon cancer with a stratified comparison based on operative risk using age (≤70 years and >70 years) and ASA score (I-II and III-IV). Lower complication and mortality rates in the screen-detected compared with non-screen-detected populations were observed for any of the operative risk groups except for mortality in young and fit patients (≤70 years with ASA score I-II). These effects reached statistical significance for complicated course in all risk groups, except for patients older than 70 years with ASA score III to IV. For patients with rectal cancer, none of the stratified risk groups revealed a significant difference in complicated course or mortality ( Figure 2D) . A nonsignificant but noteworthy trend was found toward a higher risk of complicated course and mortality after resection of screen-detected rectal cancer in frail elderly patients (age >70 years with ASA score III-IV).
Case Mix-Adjusted Comparison of Screen-Detected vs Non-Screen-Detected CRC For colon cancer, surgery of screen-detected patients was independently associated with lower odds on nonsurgical complications (adjusted odds ratio [AOR], 0.81; 95% CI, 0.73-0.91), surgical complications (AOR, 0.80; 95% CI, 0.72-0.89), and complicated course (AOR, 0.80; 95% CI, 0.71-0.90) compared with surgery for patients with colon cancer that were not screen detected ( Table 3) . Whether colon cancer was detected through screening was not associated with mortality in multivariable analysis. Referral through the screening program was not independently associated with any postoperative complication after rectal cancer surgery. However, surgery in patients with screen-detected rectal cancer was associated with a significantly higher risk of mortality compared with patients with non-screen-detected rectal cancer (AOR, 2.27; 95% CI, 1.31-3.96).
Discussion
Surgery for screen-detected colon cancer was associated with better postoperative outcomes compared with non-screendetected patients, even when an extensive case-mix adjustment was applied. This was not observed for rectal cancer. Most patient, tumor, and surgical treatment characteristics of the group of screen-detected CRC were significantly different compared with the group of non-screen-detected CRC in the same period. Besides a shift toward lower stages, patients with screen-detected cancers had fewer preoperative tumorrelated complications such as bleeding or ileus. American Society of Anesthesiologists and Charlson scores were also more favorable in patients with screen-detected CRC, although more pronounced in colon cancer than in rectal cancer. However, significantly more patients with screen-detected CRC had a BMI more than 30. Also in line with expectations, treatment differed between the screen-detected and non-screen-detected group with less need for preoperative radiotherapy, more laparoscopic procedures, fewer stomas, less extensive resections for local ingrowth, and fewer simultaneous resections of metastases in the patients with screen-detected tumors. 7255 (92) 7281 (92) . 80 1544 (98) <.001
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For patients with rectal cancer, screening did not reveal any statistical association for postoperative complications in the multivariable model. Although the case-mix-adjusted odds ratio on postoperative mortality was surprisingly higher in patients with screen-detected rectal cancer, an important remark has to be made interpreting this finding. Owing to the low event rate of mortality (n = 100) relative to the df used in the model (df = 29), the model could be less stable, thereby possibly affecting the reliability of the outcome. Also, there might be a chance of a type I statistical error in this analysis since we do not have a plausible explanation for this finding. This aside, analysis of the stratified subgroup did reveal a few additional events among the frail elderly patients and stage IV screen-detected rectal cancer. Stage IV screen-detected cancer may consist of a specific category of patients, with either aggressive tumor biology or relatively small asymptomatic primaries that eventually will develop metastases at an asymptomatic stage or patients who neglect initial symptoms and retrospectively should have been diagnosed earlier.
It is generally agreed that screening will eventually result in earlier stage at diagnosis and that this is associated with a better prognosis. [10] [11] [12] [13] However, the impact of fecal occult blood tests screening on a surgical CRC audit is less clear with several potential influences. First, earlier cancer stage will enable more nonsurgical treatment using endoscopic removal (with or without laparoscopic assistance), and these patients are not included in the DCRA. Second, more patients might be candidates for minimally invasive procedures, such as laparoscopic surgery or local excision, with a positive impact on postoperative outcomes. 14, 15 Third, screening will diagnose a group of patients at an earlier cancer stage, which is oncologically relevant, but will not have a significant impact on short-term morbidity and mortality in the DCRA. For example, a shift from T1-3N1M0 (stage III) to T1-3N0M0 (stage II) colon cancer will reduce the need for adjuvant chemotherapy and is associated with better long-term survival, but the type of surgery (segmental colonic resection) remains identical and there might not be any benefit visible in the DCRA for the in-hospital/30-day period. Finally, a (possibly small) negative effect on the overall out- 7273 (96) 7199 (95) . 03 1380 (98) <.001
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Median lymph comes in the DCRA could even exist if patients with locally advanced or metastatic tumors are diagnosed somewhat earlier by screening, making them eligible for resection, while they would otherwise have been treated by systemic or supportive therapy and therefore would not be registered in the DCRA. Amri et al 16 compared long-term outcomes in colon cancer surgery of non-screen-detected patients with screendetected patients but with the important difference that screendetected patients were referred through screening colonoscopy.
They found patients with screen-detected colon cancer to have better outcomes independent of their cancer stage. A possible contributing factor for this observation, also observed by Saraste et al, 17 is that patients in the screening program had a more extensive workup with optimized preoperative multidisciplinary team meeting discussion and preoperative visualization of the entire colon. Tumor biology may also be different in screen-detected cancers, 18, 19 such as the speed of tumor growth, tissue invasiveness, and the ease of the tumor of causing symptoms (eg, bleeding). Additionally, healthy user bias might play a role. For example, it is known that people with a low socioeconomic status are less likely to participate in a CRC screening program [20] [21] [22] [23] but have a higher risk of developing CRC and more coexisting morbidities compared with people with a high socioeconomic status. 24 The present data and the study by Amri et al 16 suggest that screen-detected colon cancer represents a different population of patients undergoing surgical resection. In the transition phase toward a fully implemented colorectal screening program, this might have implications for benchmarking surgical outcomes, possibly urging us to add screening to the case-mix model.
For rectal cancer, outcomes between screen-detected and non-screen-detected patients did not differ. One of the potential explanations might be that rectal cancer is becoming symptomatic at a relatively early stage compared with colon cancer, which reduces the differences between screen-detected and nonscreen-detected cancers.
Limitations
Besides the strength of the present study, such as the usage of population-based data, which reflect daily practice and the large numbers of patients, several limitations have to be taken into account. A certain extent of missing data are unavoidable in population-based studies. As also mentioned before, one might argue that some potential contributing factors to the difference observed were not included in the case-mix correction, such as substance abuse (eg, smoking), nutritional status prior to surgery, or other (unknown) factors. Moreover, stage distributions might also change over time independent of the screening program, making the current findings less consistent over time. Also, this study lacks information on people not participating in the screening program, in whom the FIT was false negative, or people not receiving a colonoscopy after a positive FIT owing to patient preferences. In addition, some patients with screen-detected cancers do not undergo surgical resection. These patients may undergo endoscopic removal of low-risk T1 tumors, be unfit for surgery, or have irresectable disease. Finally, although impossible to prove or quantify, the start of the screening may have already affected characteristics of the non-screen-detected CRC population through earlier identification and the creation of more awareness about the disease. Rectal cancer mortality Figure 2C not screen detected, n = 14; screen detected, n = 1. Missing values in Figure 2D not screen detected, n = 9; screen detected, n = 0. a Significant difference (χ 2 ) between screen-detected and non-screen-detected patients. Conclusions From a surgical perspective, patients diagnosed as having a CRC detected through the national FIT-based CRC screening program represent a different population. Surgery for screendetected colon cancer was associated with better postoperative outcomes compared with non-screen-detected patients, even when an extensive case-mix adjustment was applied. Future studies on surgical outcomes of CRC treatment should be aware of these differences and consequently take this into account in their comparison models. b Frequency of missing values in multivariable analysis colon: 49 (0.2%) (missing: sex, n = 10; age, n = 12; American Society of Anesthesiologists score, n = 7; previous abdominal surgery, n = 21). Frequency of missing values rectum: 191 (2%) (missing: sex, n = 8; age, n = 8; American Society of Anesthesiologists score, n = 2; tumor distance from anal verge, n = 167).
c The following factors were included in the multivariable model to correct for differences in case mix between patients: age, sex, body mass index, American
Society of Anesthesiologists score, Charlson comorbidity score, any tumor-related complication, previous abdominal surgery, pathologic tumor classification, presence of metastasis, additional resection due to tumor invasion, and additional resection due to metastasis.
d Added for the colon: location of tumor within colon.
e Significant values.
f Added for the rectum: received radiotherapy (no short-course radiotherapy with immediate surgery, short-course radiotherapy with delayed surgery, or chemoradiation/long-course radiotherapy), procedure (lower anterior resection, abdominal perineal resection, or different), clinical tumor classification, and tumor distance from anal verge.
